annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 46F VortigERN: Variation of radiotherapy target volume definition, dose to
organs at risk (OAR), and clinical target volumes using anatomic (CT) versus
combined anatomic and molecular imaging (PET-CT): Intensity-modulated
radiotherapy delivered using a tomotherapy hi art machine. (Abstract
#TPS267)
S. Chatterjee, J. Frew, J. B. Wilsdon, H. M. Mccallum, J. H. Mott, P. Stevenson, W.
Dobrowsky, R. J. Maxwell, C. G. Kelly
Brd. 46G Correlative analyses between EGFR pathways and stroma-tumor profiles in
head and neck cancer patients (HNSCC) on postoperative radiotherapy plus
cisplatin (PORTc) plus or minus gefitinib (GORTEC-GETTEC CARISSA trial):
Implications for sensitivity to gefitinib. (Abstract #TPS268)
J. Thariat, D. Grall, M. Etienne-Grimaldi, F. Penault-Llorca, M. Francoual, G. A.
Milano, D. De Raucourt, P. Garaud, R. Bensadoun, E. van-Obberghen Schilling
Brd. 46H Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical
phase II trial and correlation to retinoid and peroxisome proliferator-activated
receptor gamma receptors expression. (Abstract #TPS269)
L. P. De Oliveira, B. Haugen, M. Kane, A. Jimeno, J. Klopper
Brd. 47A Acupuncture for dysphagia after chemoradiation therapy in head and neck
cancer: An ongoing pilot, randomized, sham-controlled trial. (Abstract
#TPS270)
W. Lu, J. H. Lorch, T. A. Balboni, D. J. Sher, L. A. Goguen, C. M. Norris Jr., R. B.
Tishler, M. R. Posner, D. S. Rosenthal, R. I. Haddad
Brd. 47B Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable
adenoid cystic carcinoma of the head and neck. (Abstract #TPS271)
A. P. Kotsakis, W. E. Gooding, A. Argiris
Health Services Research
Brd. 47C A pilot study comparing a patient-centered symptom-reporting follow-up
program to standard care in patients who have completed the acute phase of
treatment for early breast cancer. (Abstract #TPS272)
M. E. Melisko, E. Mihalis, M. Ernest, H. S. Rugo, J. W. Park, M. M. Moasser, P. N.
Munster, L. Esserman
Brd. 47D Telephone-based health coaching for cognitive, affective, and quality-of-life
improvement in patient-caregiver cancer survivorship: A mixed-methods
educational intervention. (Abstract #TPS273)
D. R. Close
Brd. 47E Validation study of the patient-reported outcomes version of the common
terminology criteria for adverse events (PRO-CTCAE). (Abstract #TPS274)
A. C. Dueck, T. R. Mendoza, B. B. Reeve, J. A. Sloan, C. S. Cleeland, J. Hay, Y. Li,
A. M. O’Mara, A. Denicoff, E. M. Basch
Leukemia, Myelodysplasia, and Transplantation
Brd. 47F CPX-351: A randomized phase IIb study first-relapse patients younger than
age 65. (Abstract #TPS275)
J. E. Kolitz, J. E. Cortes, K. Paulsen, A. C. Louie
Brd. 47G A phase Ib study of oral panobinostat (LBH589) in combination with
cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory
or relapsed acute myeloid leukemia (AML). (Abstract #TPS276)
J. Krauter, O. G. Ottmann, R. F. Schlenk, M. Schaich, D. Bouscary, H. Dombret, F.
Lüdicke, H. J. Weber, I. J. Winiger
Brd. 47H The OPAL study: A phase II study to evaluate the efficacy, safety, and
tolerability of tosedostat (CHR-2797) in elderly subjects with treatment
refractory or relapsed acute myeloid leukemia. (Abstract #TPS277)
J. E. Cortes, E. J. Feldman, K. W. Yee, M. J. Toal, A. Richardson, A. Charman, N.
Flores, The OPAL Investigators
328